Plus Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
CVI Investments, Inc. and Heights Capital Management, Inc. have reported beneficial ownership of approximately 4.9% of Plus Therapeutics, Inc. common stock, primarily through warrants.
NASDAQ
Highbridge Capital Management, LLC has reported beneficial ownership of 7.1% of Plus Therapeutics, Inc. common stock, primarily through the exercise of warrants.
NASDAQ
CVI Investments, Inc. and Heights Capital Management, Inc. have jointly reported a beneficial ownership of 6.9% in Plus Therapeutics, Inc., totaling 12,368,423 shares.
NASDAQ
S.H.N. Financial Investments Ltd. has increased its beneficial ownership in Plus Therapeutics, Inc. to 1.51% of common stock.
NASDAQ
AIGH Capital Management and Orin Hirschman have disclosed a 3.9% beneficial ownership stake in Plus Therapeutics, Inc., primarily through sole dispositive power over 1,283,681 shares including warrants.
NASDAQ
SCHEDULE 13G/A: The Hewlett Fund LP Divests Entire Stake in Plus Therapeutics, Reports Zero Beneficial Ownership
The Hewlett Fund LP has filed an amended Schedule 13G, reporting zero beneficial ownership of common stock in Plus Therapeutics, Inc., indicating a complete divestment of its previous holdings.
NASDAQ
The Hewlett Fund LP has disclosed a beneficial ownership of 8.255% in Plus Therapeutics, Inc., holding 2,006,552 shares of common stock.
NASDAQ
S.H.N. Financial Investments Ltd. has reported a 9.99% beneficial ownership stake in Plus Therapeutics, Inc., comprising common stock and pre-funded warrants.
NASDAQ
AIGH Capital Management LLC and Orin Hirschman have jointly disclosed a 9.5% beneficial ownership stake in Plus Therapeutics, Inc., totaling 560,905 common shares.